Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

IBM Joins Forces with top Cancer Centers

Published: Friday, November 11, 2005
Last Updated: Friday, November 18, 2005
Bookmark and Share
IBM Collaborates with MSKCC, the Molecular Profiling Institute and Sainte-Justine Research Center.

IBM has announced that it is joining forces with Memorial Sloan-Kettering Cancer Center (MSKCC), the Molecular Profiling Institute and the CHU Sainte-Justine Research Center- Mother and Child University Hospital Center under separate agreements to help accelerate cancer research, diagnosis and treatment.

IBM and MSKCC are building an integrated information management system to improve the ability of clinicians and researchers to study long-term cancer-related illnesses, identify disease trends and determine success rates.

Funded by a $3 million grant of technology and services from IBM, MSKCC will include a comprehensive system to integrate its hospital data with text mining and related analytical capabilities into a unified information management environment to facilitate predictive analysis and research.

In addition, pathologists at MSKCC are working closely with researchers at IBM to create a searchable database for pathology reports.

IBM is also teaming with the Molecular Profiling Institute and the CHU Sainte-Justine Research Center - Mother and Child University Hospital Center under separate agreements to accelerate cancer research, diagnosis and treatment.

“This is an excellent multi-sector model that can drive integration of molecular medicine into areas where it's truly needed, including cancer detection, treatment, and ultimately prevention,” said Dr. Anna D. Barker, Deputy Director of the National Cancer Institute (NCI).

“The convergence of advanced technologies and post-genomics science will change cancer medicine in ways we cannot yet envision.”

“The NCI is enabling management of the data from this new era of biomedical research through our open source bioinformatics network, the Cancer Biomedical Informatics Grid (caBIG).”

“Capturing and managing the unprecedented amounts of information generated from new technologies, and integrating the entire process from bench to the bedside, can help usher in the era of molecular oncology - and provide a catalyst to transform all healthcare.”

Through the IBM-MSKCC pathology report project, researchers are working to create a system where information will automatically be extracted from thousands of pathology reports and mapped to a database.

Most pathology reports are written in free text, where phrases and numbers need to be deciphered by the reader in context.

Similar information could be expressed using different phrases depending on the doctor dictating the report and the year in which it was done.

Through the work of IBM, past pathology reports at MSKCC are being mapped into standards formats.

Information from the reports is being automatically extracted so that it can be organized into databases making it possible for researchers to query information easily.

“Our research requires us to look at historical information, and at Memorial Sloan-Kettering, we have one of the largest repositories of patient records and tissue samples for cancer,” said Pat Skarulis, Vice President and CIO of Memorial Sloan-Kettering Cancer Center.

“With the new functionality provided by the pathology search capability and mining we hope to will provide our staff with a greater level of insight into the data than has been available in the past,” said Dr. David Artz, Medical Director Information Systems at Memorial Sloan-Kettering.

IBM and the Molecular Profiling Institute have partnered to collaborate and harness molecular profiling technologies to help diagnose ailments and access information to determine better treatment options.

The technology being developed jointly will provide clinicians with diagnostic intelligence and analysis to assist them in making molecular distinctions when diagnosing and treating cancer patients.

It is a first step to making personalized diagnosis based on phenotype and genomic data possible and will send physicians and clinicians a tailored patient report based on the patient's complete molecular profile.

Molecular Profiling has a partnership with the Translational Genomics Research Institute (TGen) to work together to accelerate genomic discoveries from bench to bedside.

These genomic advances are communicated utilizing IBM to our physician partner organizations beginning with AmeriPath, Inc.

“Our ability to characterize an individual patient's disease at a much greater level of detail in combination with our research partner's ability to mine and translate molecular data will accelerate our applications to patient care,” said Dr. Robert Penny, Chief Executive Officer of the Molecular Profiling Institute.

“IBM's partnership with the Molecular Profiling Institute will help us get one step closer to the vision of personalized medicine based on integrated patient data and the latest advancements in molecular medicine.”

IBM is working with the CHU to help develop an informatics infrastructure, based on IBM's Clinical Genomics Solution, to better define the genetic markers for acute lymphoblastic leukemia (ALL).

Through the use of advanced technologies, the CHU's researchers will have real-time access to a body of quality data, using technology that is easy to navigate and compatible with their needs.

Clinical data that was once manually extracted from the hospital's patient file will now be electronically transmitted and merged with genomic data to create a Medical Information Repository (MIR).

This will reduce a query process from days to minutes and allow researchers to develop personalized therapies for various patients and keep longitudinal records.

“All research projects will eventually be supported from a single database and integrated infrastructure. And, starting now our physicians can access data in a way suited to their specific needs,” said Dr. Daniel Sinnett, associate professor at the University of Montreal and head of the leukemia-cancer section at the Research Center.

“This means we can avoid duplicate entries, delete nominative information from clinical systems data and provide long-term follow-up with patients well into adulthood.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Watson to Gain Ability to “See” with Planned $1B Acquisition of Merge Healthcare
Deal brings Watson technology together with leader in medical images.
Friday, August 07, 2015
IBM and Mars Launch Pioneering Effort to Drive Advances in Global Food Safety
New Sequencing the Food Supply Chain Consortium to undertake the largest-ever metagenomics study and unlock food safety insights across the supply chain.
Friday, February 06, 2015
IBM’s Big Data & Analytics Monitors Babies at INFANT Centre
INFANT Centre at University College Cork to use IBM Big Data & Analytics for real time monitoring of babies in neonatal intensive care.
Tuesday, January 27, 2015
The New York Genome Center and IBM Watson Group Collaborate
Project aims to apply advanced analytics to genomic treatment options for brain cancer patients.
Wednesday, September 10, 2014
Texas A&M System Teams with IBM to Drive Computational Sciences Research through Big Data and Analytics
The collaboration will leverage the power of big data analytics and high performance computing (HPC) systems.
Monday, February 03, 2014
IBM Commits $1.2 Billion to Expand Global Cloud Footprint, Builds Massive Network
IBM is committing to significantly expand its global network of cloud data centers.
Monday, January 27, 2014
IBM and Swiss Hospital Test New Tool for Diagnosing Cancer
The compact and easy-to-use device may help unravel tumor heterogeneity and assist in personalized treatment strategies.
Thursday, October 24, 2013
IBM’s Biomedical Analytics Platform Helps Doctors Personalise Treatment
Italy’s Istituto Nazionale dei Tumori testing new decision support solutions for cancer treatments.
Tuesday, March 20, 2012
New Silicon Probe Assists in Disease Diagnostics and Drug Discovery
Scientists have developed a flexible, non-contact microfluidic probe made from silicon that can aid researchers and pathologists to investigate critical tissue samples accurately, reducing the need for large biopsy samples.
Monday, January 16, 2012
IBM Research Aims to Build Nanoscale DNA Sequencer to Help Drive Down Cost of Personalized Genetic Analysis
New advanced research effort to demonstrate a silicon-based “DNA Transistor” could help pave the way to read human DNA easily.
Thursday, October 08, 2009
IBM and University Researchers to Develop Research Tools to Improve Cancer Patient Outcomes
Advanced imaging and computer technologies aimed at providing for reliable prognosis leading to more personalized treatment.
Wednesday, February 13, 2008
IBM Discovery Could Shed Light on Workings of the Human Genome
IBM researchers discover numerous DNA patterns shared by areas of the human genome.
Wednesday, April 26, 2006
IBM create smallest solid-state light emitter with Nanotubes

Thursday, May 08, 2003
IBM and IDBS Form Global Strategic Alliance

Wednesday, April 02, 2003
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
Dementia Linked to Deficient DNA Repair
Mutant forms of breast cancer factor 1 (BRCA1) are associated with breast and ovarian cancers but according to new findings, in the brain the normal BRCA1 gene product may also be linked to Alzheimer’s disease.
Using Drug-Susceptible Parasites to Fight Drug Resistance
Researchers at the University of Georgia have developed a model for evaluating a potential new strategy in the fight against drug-resistant diseases.
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
New Discovery Sheds Light on Disease Risk
Gaps between genes interact to influence the risk of acquiring disease.
How Cells ‘Climb’ to Build Fruit Fly Tracheas
Mipp1 protein helps cells sprout “fingers” for gripping.
Research Finding Could Lead to Targeted Therapies for IBD
Findings published online in Cell Reports.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos